Suppr超能文献

胸腔积脓的手术治疗与非手术治疗

Surgical versus non-surgical management for pleural empyema.

作者信息

Redden Mark D, Chin Tze Yang, van Driel Mieke L

机构信息

Ipswich Hospital, Ipswich, Queensland, Australia.

The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia, 4032.

出版信息

Cochrane Database Syst Rev. 2017 Mar 17;3(3):CD010651. doi: 10.1002/14651858.CD010651.pub2.

Abstract

BACKGROUND

Empyema refers to pus in the pleural space, commonly due to adjacent pneumonia, chest wall injury, or a complication of thoracic surgery. A range of therapeutic options are available for its management, ranging from percutaneous aspiration and intercostal drainage to video-assisted thoracoscopic surgery (VATS) or thoracotomy drainage. Intrapleural fibrinolytics may also be administered following intercostal drain insertion to facilitate pleural drainage. There is currently a lack of consensus regarding optimal treatment.

OBJECTIVES

To assess the effectiveness and safety of surgical versus non-surgical treatments for complicated parapneumonic effusion or pleural empyema.

SEARCH METHODS

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 9), MEDLINE (Ebscohost) (1946 to July week 3 2013, July 2015 to October 2016) and MEDLINE (Ovid) (1 May 2013 to July week 1 2015), Embase (2010 to October 2016), CINAHL (1981 to October 2016) and LILACS (1982 to October 2016) on 20 October 2016. We searched ClinicalTrials.gov and WHO International Clinical Trials Registry Platform for ongoing studies (December 2016).

SELECTION CRITERIA

Randomised controlled trials that compared a surgical with a non-surgical method of management for all age groups with pleural empyema.

DATA COLLECTION AND ANALYSIS

Two review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked the data for accuracy. We contacted trial authors for additional information. We assessed the quality of the evidence using the GRADE approach.

MAIN RESULTS

We included eight randomised controlled trials with a total of 391 participants. Six trials focused on children and two on adults. Trials compared tube thoracostomy drainage (non-surgical), with or without intrapleural fibrinolytics, to either VATS or thoracotomy (surgical) for the management of pleural empyema. Assessment of risk of bias for the included studies was generally unclear for selection and blinding but low for attrition and reporting bias. Data analyses compared thoracotomy versus tube thoracostomy and VATS versus tube thoracostomy. We pooled data for meta-analysis where appropriate. We performed a subgroup analysis for children along with a sensitivity analysis for studies that used fibrinolysis in non-surgical treatment arms.The comparison of open thoracotomy versus thoracostomy drainage included only one study in children, which reported no deaths in either treatment arm. However, the trial showed a statistically significant reduction in mean hospital stay of 5.90 days for those treated with primary thoracotomy. It also showed a statistically significant reduction in procedural complications for those treated with thoracotomy compared to thoracostomy drainage. We downgraded the quality of the evidence for length of hospital stay and procedural complications outcomes to moderate due to the small sample size.The comparison of VATS versus thoracostomy drainage included seven studies, which we pooled in a meta-analysis. There was no statistically significant difference in mortality or procedural complications between groups. This was true for both adults and children with or without fibrinolysis. However, mortality data were limited: one study reported one death in each treatment arm, and seven studies reported no deaths. There was a statistically significant reduction in mean length of hospital stay for those treated with VATS. The subgroup analysis showed the same result in adults, but there was insufficient evidence to estimate an effect for children. We could not perform a separate analysis for fibrinolysis for this outcome because all included studies used fibrinolysis in the non-surgical arms. We downgraded the quality of the evidence to low for mortality (due to wide confidence intervals and indirectness), and moderate for other outcomes in this comparison due to either high heterogeneity or wide confidence intervals.

AUTHORS' CONCLUSIONS: Our findings suggest there is no statistically significant difference in mortality between primary surgical and non-surgical management of pleural empyema for all age groups. Video-assisted thoracoscopic surgery may reduce length of hospital stay compared to thoracostomy drainage alone.There was insufficient evidence to assess the impact of fibrinolytic therapy.A number of common outcomes were reported in the included studies that were not directly examined in our primary and secondary outcomes. These included duration of chest tube drainage, duration of fever, analgesia requirement, and total cost of treatment. Future studies focusing on patient-centred outcomes, such as patient functional scores, and other clinically relevant outcomes, such as radiographic improvement, treatment failure rates, and amount of fluid drainage, are needed to inform clinical decisions.

摘要

背景

脓胸是指胸膜腔内有脓液,通常由于邻近肺炎、胸壁损伤或胸外科手术并发症引起。其治疗有多种选择,从经皮穿刺抽吸和肋间引流到电视辅助胸腔镜手术(VATS)或开胸引流。肋间引流管插入后也可给予胸膜内纤维蛋白溶解剂以促进胸膜引流。目前对于最佳治疗尚无共识。

目的

评估手术与非手术治疗复杂性肺炎旁胸腔积液或胸膜脓胸的有效性和安全性。

检索方法

我们于2016年10月20日检索了Cochrane对照试验中心注册库(CENTRAL)(2016年第9期)、MEDLINE(Ebscohost)(1946年至2013年7月第3周、2015年7月至2016年10月)和MEDLINE(Ovid)(2013年5月1日至2015年7月第1周)、Embase(2010年至2016年10月)、CINAHL(1981年至2016年10月)和LILACS(1982年至2016年10月)。我们检索了ClinicalTrials.gov和世界卫生组织国际临床试验注册平台以查找正在进行的研究(2016年12月)。

入选标准

比较手术与非手术治疗方法用于所有年龄组胸膜脓胸的随机对照试验。

数据收集与分析

两位综述作者独立评估试验是否纳入及偏倚风险,提取数据并检查数据准确性。我们联系试验作者获取更多信息。我们使用GRADE方法评估证据质量。

主要结果

我们纳入了八项随机对照试验,共391名参与者。六项试验针对儿童,两项针对成人。试验比较了胸腔闭式引流(非手术),有无胸膜内纤维蛋白溶解剂,与VATS或开胸手术(手术)用于胸膜脓胸的治疗。纳入研究的选择和盲法偏倚风险评估通常不明确,但失访和报告偏倚风险低。数据分析比较了开胸手术与胸腔闭式引流以及VATS与胸腔闭式引流。我们在适当情况下汇总数据进行荟萃分析。我们对儿童进行了亚组分析,并对在非手术治疗组中使用纤维蛋白溶解剂的研究进行了敏感性分析。开胸手术与胸腔闭式引流的比较仅包括一项儿童研究,该研究报告两个治疗组均无死亡。然而,该试验显示接受一期开胸手术治疗的患者平均住院时间在统计学上显著缩短5.90天。与胸腔闭式引流相比,开胸手术治疗的患者手术并发症在统计学上也显著减少。由于样本量小,我们将住院时间和手术并发症结局的证据质量降至中等。VATS与胸腔闭式引流的比较包括七项研究,我们将其汇总进行荟萃分析。两组之间的死亡率或手术并发症无统计学显著差异。无论有无纤维蛋白溶解剂,成人和儿童均如此。然而,死亡率数据有限:一项研究报告每个治疗组有1例死亡,七项研究报告无死亡。接受VATS治疗的患者平均住院时间在统计学上显著缩短。亚组分析在成人中显示了相同结果,但没有足够证据估计对儿童的影响。由于所有纳入研究在非手术组中都使用了纤维蛋白溶解剂,我们无法对该结局进行纤维蛋白溶解剂的单独分析。由于置信区间宽和间接性,我们将死亡率的证据质量降至低等,对于该比较中的其他结局,由于高度异质性或宽置信区间,证据质量降至中等。

作者结论

我们的研究结果表明,所有年龄组胸膜脓胸的一期手术与非手术治疗在死亡率方面无统计学显著差异。与单纯胸腔闭式引流相比,电视辅助胸腔镜手术可能缩短住院时间。没有足够证据评估纤维蛋白溶解疗法的影响。纳入研究报告了一些在我们的主要和次要结局中未直接检查的常见结局。这些包括胸管引流持续时间、发热持续时间、镇痛需求和治疗总成本。未来需要关注以患者为中心的结局,如患者功能评分,以及其他临床相关结局,如影像学改善、治疗失败率和引流量,以指导临床决策。

相似文献

1
Surgical versus non-surgical management for pleural empyema.
Cochrane Database Syst Rev. 2017 Mar 17;3(3):CD010651. doi: 10.1002/14651858.CD010651.pub2.
2
WITHDRAWN: Surgical versus non-surgical management of pleural empyema.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD001956. doi: 10.1002/14651858.CD001956.pub3.
3
Surgical versus non-surgical management of pleural empyema.
Cochrane Database Syst Rev. 2005 Oct 19(4):CD001956. doi: 10.1002/14651858.CD001956.pub2.
4
Surgical versus non-surgical management of pleural empyema.
Cochrane Database Syst Rev. 2002(2):CD001956. doi: 10.1002/14651858.CD001956.
5
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.
Cochrane Database Syst Rev. 2018 Jul 9;7(7):CD011492. doi: 10.1002/14651858.CD011492.pub2.
6
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013307. doi: 10.1002/14651858.CD013307.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.
Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD010516. doi: 10.1002/14651858.CD010516.pub2.
10
Heliox for croup in children.
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD006822. doi: 10.1002/14651858.CD006822.pub6.

引用本文的文献

1
Use of Intrapleural Alteplase in the Treatment of Parapneumonic Effusion in Children: A Report of a 10-year Experience.
J Pediatr Pharmacol Ther. 2025 Aug;30(4):484-493. doi: 10.5863/JPPT-24-00057. Epub 2025 Aug 11.
10
Enzymatic therapy video-assisted thoracoscopic surgery for pleural infections: a systematic review and meta-analysis.
ERJ Open Res. 2025 Mar 3;11(2). doi: 10.1183/23120541.00619-2024. eCollection 2025 Mar.

本文引用的文献

2
VATS or urokinase for treatment of empyema?
Indian Pediatr. 2015 Jan;52(1):57-9. doi: 10.1007/s13312-015-0567-4.
3
Urokinase versus VATS for treatment of empyema: a randomized multicenter clinical trial.
Pediatrics. 2014 Nov;134(5):e1301-7. doi: 10.1542/peds.2013-3935.
4
The role of thoracoscopic debridement in the treatment of parapneumonic empyema.
Asian Cardiovasc Thorac Ann. 2013 Aug;21(4):443-6. doi: 10.1177/0218492312466858. Epub 2013 Jul 11.
5
ICD Versus VATS as Primary Treatment in Fibrinopurulent Stage of Empyema Thoracis.
J Clin Diagn Res. 2013 Dec;7(12):2855-8. doi: 10.7860/JCDR/2013/7228.3776. Epub 2013 Dec 15.
8
Multidisciplinary management of malignant pleural effusion.
J Surg Oncol. 2012 Jun 1;105(7):731-8. doi: 10.1002/jso.22100. Epub 2011 Sep 29.
9
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
N Engl J Med. 2011 Aug 11;365(6):518-26. doi: 10.1056/NEJMoa1012740.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验